Computational Comparison of Imidazoline Association with the 12 Binding Site in Human Monoamine Oxidases

被引:14
作者
Basile, Livia [1 ]
Pappalardo, Matteo [2 ]
Guccione, Salvatore [1 ,3 ]
Milardi, Danilo [4 ]
Ramsay, Rona R. [5 ]
机构
[1] Univ Catania, Scuola Super Catania, Etnalead Srl, I-95123 Catania, Italy
[2] Univ Catania, Dipartimento Sci Chim, I-95125 Catania, Italy
[3] Univ Catania, Dipartimento Sci Farmaco, I-95125 Catania, Italy
[4] Univ Catania, IBB, CNR, UOS Catania,Dipartimento Sci Chim, I-95125 Catania, Italy
[5] Univ St Andrews, St Andrews KY16 8QP, Fife, Scotland
关键词
MOLECULAR-DYNAMICS; LIGAND-BINDING; HUMAN BRAIN; INHIBITION; POTENTIATION; TRANYLCYPROMINE; DERIVATIVES; RESOLUTION; RECEPTORS; LIVER;
D O I
10.1021/ci400346k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Imidazoline ligands in I2-type binding sites in the brain alter monoamine turnover and release. One example of an 12 binding site characterized by binding studies, kinetics, and crystal structure has been described in monoamine oxidase B (MAO B). MAO A also binds imidazolines but has a different active site structure. Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B. The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity. Binding to the tranylc-ypromine-modified MAO B was with high affinity and in the entrance cavity as in the crystal structure, but the energies of interaction with the native MAO B were less favorable. Molecular dynamics revealed that the entrance cavity of MAO B after tranylcypromine modification is both smaller and less flexible. This change in the presence of tranylcypromine may be responsible for the greater affinity of tranylcypromine-modified MAO B for imidazoline ligands.
引用
收藏
页码:1200 / 1207
页数:8
相关论文
共 31 条
[1]   Steered Molecular Dynamics Simulations Reveal Important Mechanisms in Reversible Monoamine Oxidase B Inhibition [J].
Allen, William J. ;
Bevan, David R. .
BIOCHEMISTRY, 2011, 50 (29) :6441-6454
[2]   CDNA CLONING OF HUMAN-LIVER MONOAMINE OXIDASE-A AND OXIDASE-B - MOLECULAR-BASIS OF DIFFERENCES IN ENZYMATIC-PROPERTIES [J].
BACH, AWJ ;
LAN, NC ;
JOHNSON, DL ;
ABELL, CW ;
BEMBENEK, ME ;
KWAN, SW ;
SEEBURG, PH ;
SHIH, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4934-4938
[3]   MOLECULAR-DYNAMICS WITH COUPLING TO AN EXTERNAL BATH [J].
BERENDSEN, HJC ;
POSTMA, JPM ;
VANGUNSTEREN, WF ;
DINOLA, A ;
HAAK, JR .
JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (08) :3684-3690
[4]   Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures [J].
Binda, C ;
Li, M ;
Hubálek, F ;
Restelli, N ;
Edmondson, DE ;
Mattevi, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (17) :9750-9755
[5]   Potentiation of Ligand Binding through Cooperative Effects in Monoamine Oxidase B [J].
Bonivento, Daniele ;
Milczek, Erika M. ;
McDonald, G. Reid ;
Binda, Claudia ;
Holt, Andrew ;
Edmondson, Dale E. ;
Mattevi, Andrea .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (47) :36849-36856
[6]  
CARPENE C, 1995, J PHARMACOL EXP THER, V272, P681
[7]   Imidazoline binding sites and their ligands: An overview of the different chemical structures [J].
Dardonville, C ;
Rozas, I .
MEDICINAL RESEARCH REVIEWS, 2004, 24 (05) :639-661
[8]   Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B [J].
De Colibus, L ;
Li, M ;
Binda, C ;
Lustig, A ;
Edmondson, DE ;
Mattevi, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (36) :12684-12689
[9]   A SMOOTH PARTICLE MESH EWALD METHOD [J].
ESSMANN, U ;
PERERA, L ;
BERKOWITZ, ML ;
DARDEN, T ;
LEE, H ;
PEDERSEN, LG .
JOURNAL OF CHEMICAL PHYSICS, 1995, 103 (19) :8577-8593
[10]   I-2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease [J].
GargalidisMoudanos, C ;
Pizzinat, N ;
JavoyAgid, F ;
Remaury, A ;
Parini, A .
NEUROCHEMISTRY INTERNATIONAL, 1997, 30 (01) :31-36